<DOC>
	<DOC>NCT01306214</DOC>
	<brief_summary>This trial will evaluate use of BI 10773 as add-on to insulin regimen alone or with metformin in patients with typr 2 diabetes. Both lowering glucose and HbA1c and reducing the use of insulin in this population would provide significant new information for the BI 10773 use and would offer a potential new therapeutic option in this population.</brief_summary>
	<brief_title>Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criteria: 1. Diagnosis of T2DM prior to informed consent 2. Male and female patients on diet and exercise regimen who are pretreated with multiple daily injections (MDI) of insulin alone or in combination with immediate or extended release metformin 3. Stable metformin therapy: daily dose &gt;=1500 mg/day or maximum tolerated dose 4. HbA1c &gt;=7.5% and &lt;=10% at screening Exclusion criteria: 1. Uncontrolled hyperglycemia with a glucose level &gt;240 mg/dl (&gt;13.3 mmol/L) after an overnight fast during placebo runin 2. Any contraindications to metformin according to the local label 3. Acute coronary syndrome, stroke or TIA within 3 months prior to informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>